N@N

Sumant Kulkarni Maintained (ACAD) at Strong Buy with Increased Target to $26 on, Mar 14th, 2023

Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Increased Target from $24 to $26 on, Mar 14th, 2023.

Sumant has made no other calls on ACAD in the last 4 months.

There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 4 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $19 on, Monday, March 13th, 2023
• Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
• Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023
• Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022

This is the rating of the analyst that currently disagrees with Sumant

---

• Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023

Contributing Sources

---